Peg L-Asperigine Injection
Peg L-Asparaginase Injection (Pegaspargase) is an antineoplastic (anticancer) medication used in combination chemotherapy regimens for the treatment of Acute Lymphoblastic Leukemia (ALL). It is a pegylated form of the enzyme L-Asparaginase, which works by depleting asparagine, an amino acid essential for the survival of leukemic cells.
Pegaspargase is typically administered as part of multi-agent chemotherapy protocols in pediatric and adult ALL patients, particularly in those who are hypersensitive to native L-Asparaginase.
This formulation offers a longer half-life due to its pegylation, allowing for less frequent dosing compared to standard L-Asparaginase. The extended duration reduces the need for multiple infusions, improving patient compliance and minimizing hospital visits.
Administration is via intravenous (IV) infusion or intramuscular (IM) injection, with dosage and frequency determined by the oncologist based on treatment protocols.
Common side effects include nausea, vomiting, hypersensitivity reactions, elevated liver enzymes, pancreatitis, and coagulation abnormalities. Patients receiving Pegaspargase require regular monitoring for liver function, pancreatic enzymes, and clotting parameters.
Store Peg L-Asparaginase Injection in a refrigerator at 2°C to 8°C. Do not freeze or shake the vial.
Peg L-Asparaginase Injection (Pegaspargase)
Peg L-Asparaginase Injection, also known as Pegaspargase, is a pegylated enzyme used in the treatment of Acute Lymphoblastic Leukemia (ALL), a fast-growing cancer affecting the blood and bone marrow. It works by depleting asparagine, an essential amino acid for leukemic cell survival. Since leukemia cells are unable to produce asparagine on their own, Pegaspargase effectively halts their growth, leading to programmed cell death.
This formulation is a modified version of native L-Asparaginase, conjugated with polyethylene glycol (PEG). As a result, it offers enhanced stability, a prolonged half-life, and reduced risk of immune response. These benefits allow for less frequent dosing—usually once every two weeks—making it a preferred choice in modern ALL treatment regimens.
Indications
- First-line treatment of Acute Lymphoblastic Leukemia (ALL) in both pediatric and adult patients
- Management of patients who have shown hypersensitivity to non-pegylated forms of L-Asparaginase
Dosage and Administration
Pegaspargase may be given via intravenous (IV) or intramuscular (IM) injection, depending on the specific treatment protocol. The dose is typically calculated based on body surface area (BSA) and in accordance with the prescribed chemotherapy regimen.
Monitoring and Precautions
Patients must undergo close monitoring for potential side effects such as:
- Hypersensitivity or allergic reactions (including anaphylaxis)
- Pancreatitis
- Elevated blood sugar (hyperglycemia)
- Liver toxicity
- Blood clotting issues (thrombosis or coagulopathy)
Therefore, routine blood tests—including liver function, pancreatic enzymes, and coagulation profiles—are essential throughout treatment.
Contraindications
Avoid Pegaspargase in patients with the following conditions:
- History of severe allergic reaction to Pegaspargase
- Active or history of pancreatitis
- Severe bleeding disorders or thrombotic events related to L-Asparaginase
Storage Instructions
Store the vials in a refrigerator at 2°C to 8°C. Do not freeze or shake the product, as this may damage its effectiveness and stability.
Explore More
For a comprehensive range of oncology medications and supportive cancer care therapies, browse our
Medicine Category. Visit our
online pharmacy shop to explore a wide variety of pharmaceutical products.
Related products
